NASDAQ:CBIOCatalyst Biosciences Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Catalyst Biosciences Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $7.80 -0.08 (-1.02 %) (As of 06/5/2020 04:00 PM ET) Add Compare Share Today's Range$7.67Now: $7.80▼$7.9750-Day Range$4.82MA: $6.35▼$7.8852-Week Range$3.43Now: $7.80▼$9.96Volume84,300 shsAverage Volume240,318 shsMarket Capitalization$94.20 millionP/E RatioN/ADividend YieldN/ABeta2.39 ProfileAnalyst RatingsAdvanced ChartCompetitorsDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines to address hematology indications. Its product pipeline includes marzeptacog alfa, a Factor VIIa variant that is in a Phase II/III clinical trial for the prophylactic treatment of individuals with severe hemophilia A and B with inhibitors. The company is also developing Dalcinonacog alfa, a Factor IX drug, which has completed enrollment of a Phase I/II subcutaneous dosing trial for the prophylactic treatment of individuals with hemophilia B; CB 2679d-GT, a FIX gene therapy for the treatment of hemophilia B; and CB 2782, an anti-C3 protease program for the treatment of dry age-related macular degeneration (AMD), as well as CB 1965a, a Factor Xa therapeutic program used as a universal procoagulant. Catalyst Biosciences, Inc. has collaboration agreement with Pfizer, Inc. for the development of human Factor VIIa products; and ISU Abxis. The company has strategic research collaboration with Mosaic Biosciences, Inc. to develop intravitreal anti-complement factor 3 products for the treatment of dry AMD and other retinal diseases. The company was founded in 2002 and is headquartered in South San Francisco, California.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingCatalyst Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $22.50, Catalyst Biosciences has a potential upside of 188.5% from its current price of $7.80.Amount of Analyst CoverageCatalyst Biosciences has only been the subject of 1 research reports in the past 90 days. Previous Next 2.5 Community Rank Outperform VotesCatalyst Biosciences has received 273 “outperform” votes. (Add your “outperform” vote.)Underperform VotesCatalyst Biosciences has received 266 “underperform” votes. (Add your “underperform” vote.)Community SentimentCatalyst Biosciences has received 50.65% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Catalyst Biosciences and other stocks. Vote “Outperform” if you believe CBIO will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CBIO will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldCatalyst Biosciences does not currently pay a dividend.Dividend GrowthCatalyst Biosciences does not have a long track record of dividend growth. Previous Next 4.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Catalyst Biosciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $43,935.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 4.00% of the stock of Catalyst Biosciences is held by insiders.Percentage Held by Institutions89.11% of the stock of Catalyst Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Catalyst Biosciences are expected to decrease in the coming year, from ($3.37) to ($3.54) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Catalyst Biosciences is -2.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Catalyst Biosciences is -2.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCatalyst Biosciences has a P/B Ratio of 1.37. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™2.00 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:CBIO Previous Symbol CUSIP87611R30 CIK1124105 Webwww.catalystbiosciences.com Phone650-871-0761Debt Debt-to-Equity Ratio0.01 Current Ratio9.13 Quick Ratio9.13Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$10,000.00 Price / Sales9,420.06 Cash FlowN/A Price / Cash FlowN/A Book Value$5.68 per share Price / Book1.37Profitability EPS (Most Recent Fiscal Year)($4.60) Net Income$-55,180,000.00 Net MarginsN/A Return on Equity-51.89% Return on Assets-43.94%Miscellaneous Employees21 Outstanding Shares12,077,000Market Cap$94.20 million Next Earnings Date8/6/2020 (Estimated) OptionableOptionable NASDAQ:CBIO Rates by TradingView Receive CBIO News and Ratings via Email Sign-up to receive the latest news and ratings for CBIO and its competitors with MarketBeat's FREE daily newsletter. Catalyst Biosciences (NASDAQ:CBIO) Frequently Asked Questions How has Catalyst Biosciences' stock been impacted by COVID-19 (Coronavirus)? Catalyst Biosciences' stock was trading at $4.83 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, CBIO stock has increased by 61.5% and is now trading at $7.80. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Catalyst Biosciences? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Catalyst Biosciences in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Catalyst Biosciences. When is Catalyst Biosciences' next earnings date? Catalyst Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Catalyst Biosciences. How were Catalyst Biosciences' earnings last quarter? Catalyst Biosciences Inc (NASDAQ:CBIO) issued its earnings results on Monday, May, 11th. The biopharmaceutical company reported ($0.28) EPS for the quarter, beating the Zacks' consensus estimate of ($0.36) by $0.08. The biopharmaceutical company had revenue of $16.37 million for the quarter. View Catalyst Biosciences' earnings history. When did Catalyst Biosciences' stock split? How did Catalyst Biosciences' stock split work? Shares of Catalyst Biosciences reverse split before market open on Monday, February 13th 2017. The 1-15 reverse split was announced on Friday, February 10th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 10th 2017. An investor that had 100 shares of Catalyst Biosciences stock prior to the reverse split would have 7 shares after the split. What price target have analysts set for CBIO? 2 analysts have issued 1 year price targets for Catalyst Biosciences' shares. Their forecasts range from $20.00 to $25.00. On average, they expect Catalyst Biosciences' stock price to reach $22.50 in the next year. This suggests a possible upside of 188.5% from the stock's current price. View analysts' price targets for Catalyst Biosciences. Has Catalyst Biosciences been receiving favorable news coverage? Media coverage about CBIO stock has been trending extremely negative on Saturday, according to InfoTrie. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Catalyst Biosciences earned a daily sentiment score of -4.4 on InfoTrie's scale. They also assigned headlines about the biopharmaceutical company a news buzz of 5.0 out of 10, indicating that recent news coverage is somewhat likely to have an effect on the stock's share price in the near term. View the latest news aboutCatalyst Biosciences. Who are some of Catalyst Biosciences' key competitors? Some companies that are related to Catalyst Biosciences include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Immunomedics (IMMU). View all competitors. What other stocks do shareholders of Catalyst Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Catalyst Biosciences investors own include Baozun (BZUN), Inovio Pharmaceuticals (INO), NovaBay Pharmaceuticals (NBY), NovaBay Pharmaceuticals (NBY), Celsion (CLSN), Sangamo Therapeutics (SGMO), Sarepta Therapeutics (SRPT), Amarin (AMRN), Catalyst Pharmaceuticals (CPRX) and Protalix Biotherapeutics (PLX). Who are Catalyst Biosciences' key executives? Catalyst Biosciences' management team includes the following people: Dr. Nassim Usman, Pres, CEO & Director (Age 59)Mr. Fletcher Payne, Chief Financial Officer (Age 56)Dr. Howard Levy, Chief Medical Officer (Age 65)Dr. Charles S. Craik, Co-Founder & Chairman of Scientific Advisory BoardMr. Andrew Hetherington M.B.A., Sr. VP of Technical Operations What is Catalyst Biosciences' stock symbol? Catalyst Biosciences trades on the NASDAQ under the ticker symbol "CBIO." Who are Catalyst Biosciences' major shareholders? Catalyst Biosciences' stock is owned by many different retail and institutional investors. Top institutional investors include Stonepine Capital Management LLC (8.44%), Prosight Management LP (3.17%), BlackRock Inc. (2.32%), Two Sigma Investments LP (1.72%), Two Sigma Advisers LP (1.60%) and Geode Capital Management LLC (0.98%). Company insiders that own Catalyst Biosciences stock include Eddie Williams, Howard Levy, John P Richard, Nassim Usman and Veronica Cai. View institutional ownership trends for Catalyst Biosciences. Which major investors are selling Catalyst Biosciences stock? CBIO stock was sold by a variety of institutional investors in the last quarter, including Two Sigma Investments LP, Prosight Management LP, and Deutsche Bank AG. View insider buying and selling activity for Catalyst Biosciences. Which major investors are buying Catalyst Biosciences stock? CBIO stock was acquired by a variety of institutional investors in the last quarter, including Stonepine Capital Management LLC, Connor Clark & Lunn Investment Management Ltd., Two Sigma Advisers LP, Squarepoint Ops LLC, Verity Asset Management Inc., Colorado Capital Management Inc., Engineers Gate Manager LP, and Geode Capital Management LLC. Company insiders that have bought Catalyst Biosciences stock in the last two years include Eddie Williams, Howard Levy, John P Richard, Nassim Usman, and Veronica Cai. View insider buying and selling activity for Catalyst Biosciences. How do I buy shares of Catalyst Biosciences? Shares of CBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Catalyst Biosciences' stock price today? One share of CBIO stock can currently be purchased for approximately $7.80. How big of a company is Catalyst Biosciences? Catalyst Biosciences has a market capitalization of $94.20 million and generates $10,000.00 in revenue each year. The biopharmaceutical company earns $-55,180,000.00 in net income (profit) each year or ($4.60) on an earnings per share basis. Catalyst Biosciences employs 21 workers across the globe. What is Catalyst Biosciences' official website? The official website for Catalyst Biosciences is www.catalystbiosciences.com. How can I contact Catalyst Biosciences? Catalyst Biosciences' mailing address is 611 GATEWAY BLVD. SUITE 710, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-871-0761 or via email at [email protected] This page was last updated on 6/6/2020 by MarketBeat.com Staff
